Corcept Therapeutics
NEWS
Otsuka and Lunbeck report positive Phase III results in agitation in Alzheimer’s, Acer’s vEDS program hits Phase III and BridgeBio’s primary hyperoxaluria type 1 program progresses.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
It’s a promising day for advanced ovarian cancer research as two biopharma companies achieved positive results. Here’s what you need to know about research.
After yesterday’s big plunge in the stock market, and today with the Dow Jones Industrial Average dropping more than 500 points after opening, but mostly recovering, volatility appears to be the key word to describe the stock market.
A look at two life science companies that are expected to grow more than 67 percent over the next five years.
When you think about it, most small biotech companies are odd investments.
JOBS
IN THE PRESS